The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

CD38 levels are associated with response and complement inhibitors contribute to resistance in myeloma patients treated with daratumumab.

Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. Blood. 2016 Jun 15. pii: blood-2016-03-703439. [Epub ahead of print] READ MORE

Posted: June 23, 2016

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P. J Immunol. 2016 Jun 17. pii: 1501351. [Epub ahead of print] READ MORE

Posted: June 23, 2016

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T. J Clin Oncol. 2016 Jun 20. pii: JCO667295. [Epub ahead of print] READ MORE

Posted: June 23, 2016

Page 22 of 87« First...10...2021222324...304050...Last »